Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C Academic Article Article uri icon

Overview

MeSH Major

  • Adenine
  • Antiviral Agents
  • Hepatitis B
  • Hepatitis B Core Antigens
  • Hepatitis B Vaccines
  • Hepatitis B virus
  • Liver Transplantation
  • Organophosphonates
  • Tissue Donors

abstract

  • A spectrum of significant pulmonary toxicity, including bronchiolitis obliterans organizing pneumonia and interstitial pneumonitis, can occur with interferon or pegylated interferon in combination with ribavirin. Though pulmonary toxicity of interferon is well known, these cases represent the first cases reported in the literature with combination therapy. It is likely that pulmonary toxicity may not be investigated in patients on combination therapy because of the frequent pulmonary symptoms with ribavirin. Though usually reversible, at least one case has required long-term steroids with inadequate resolution. Though pulmonary toxicity is rare, symptoms which are more than mild or progressive in nature should likely be investigated.

publication date

  • September 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0002-9270(02)04356-3

PubMed ID

  • 12358269

Additional Document Info

start page

  • 2432

end page

  • 40

volume

  • 97

number

  • 9